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Abstract
Background: Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly
assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR.
This method carries significant intra- and inter-observer variability. Automatic scoring of Ki-67 with digital image
analysis (qIHC) or assessment of MKI67 gene expression with RT-qPCR may improve diagnostic accuracy.
Methods: Ki-67 IHC visual assessment was compared to the IHC nuclear tool (AperioTM) on core biopsies from a
randomized neoadjuvant clinical trial. Expression of ESR1, PGR and MKI67 by RT-qPCR was performed on RNA
extracted from the same formalin-fixed paraffin-embedded tissue. Concordance between the three methods
(vIHC, qIHC and RT-qPCR) was assessed for all 3 markers. The potential of Ki-67 IHC and RT-qPCR to predict
pathological complete response (pCR) was evaluated using ROC analysis and non-parametric Mann-Whitney Test.
Results: Correlation between methods (qIHC versus RT-qPCR) was high for ER and PgR (spearman´s r = 0.82,
p < 0.0001 and r = 0.86, p < 0.0001, respectively) resulting in high levels of concordance using predefined cut-offs.
When comparing qIHC of ER and PgR with RT-qPCR of ESR1 and PGR the overall agreement was 96.6 and 91.4%,
respectively, while overall agreement of visual IHC with RT-qPCR was slightly lower for ER/ESR1 and PR/PGR
(91.2 and 92.9%, respectively). In contrast, only a moderate correlation was observed between qIHC and RT-qPCR
continuous data for Ki-67/MKI67 (Spearman’s r = 0.50, p = 0.0001). Up to now no predictive cut-off for Ki-67
assessment by IHC has been established to predict response to neoadjuvant chemotherapy. Setting the desired
sensitivity at 100%, specificity for the prediction of pCR (ypT0ypN0) was significantly higher for mRNA than for
protein (68.9% vs. 22.2%). Moreover, the proliferation levels in patients achieving a pCR versus not differed
significantly using MKI67 RNA expression (Mann-Whitney p = 0.002), but not with qIHC of Ki-67 (Mann-Whitney
p = 0.097) or vIHC of Ki-67 (p = 0.131).
Conclusion: Digital image analysis can successfully be implemented for assessing ER, PR and Ki-67. IHC for ER
and PR reveals high concordance with RT-qPCR. However, RT-qPCR displays a broader dynamic range and higher
sensitivity than IHC. Moreover, correlation between Ki-67 qIHC and RT-qPCR is only moderate and RT-qPCR with
MammaTyper® outperforms qIHC in predicting pCR. Both methods yield improvements to error-prone manual
scoring of Ki-67. However, RT-qPCR was significantly more specific.
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Background
The proliferative activity of individual cells is a hallmark
of tumor biological aggressiveness and a key determinant
of sensitivity to (neo)adjuvant chemotherapy, thus being
among the principal factors guiding clinical management
in primary breast cancer [1, 2]. The most widely used
method to assess proliferation as well as hormone recep-
tor expression is immunohistochemistry (IHC).
Nuclear staining of the nuclear antigen Ki-67 is most
widely used as a surrogate for proliferative activity. Ki-
67 is present in the cell nucleus throughout all stages
of the cell-cycle excluding the resting phase G0 [3].
The recently proposed St Gallen recommendations for
the identification of the intrinsic subtypes using surro-
gate pathologic-based definitions have underlined the
value of Ki-67 as a clinical tool in routine clinical prac-
tice [2]. Ki-67 is recommended as a valuable factor to
distinguish between Luminal A- and B-like tumors, a
fundamental distinction in clinical decision-making
today. [4–6].
Despite its widespread use, driven by the premise of
solving delicate therapeutic dilemmas combined with
several advantages such as universal accessibility, easy
application and low cost, the assessment of Ki-67, ER
and PR is affected by technical and observer-based
variabilities of the IHC method [7, 8]. This can be illus-
trated by observations, that tumors with as little as 1%
positive nuclei still respond to anti-hormonal treat-
ment, which indicates that tumor cells lacking nuclear
ER staining within in these tumors do have some
extend of ER expression rendering them sensitive to es-
trogen deprivation or estrogen receptor blockade [9].
While the clinical role particularly of ER testing by IHC
is well established, the clinical utility of Ki-67 is still
controversial [10]. The reason lies in a series of analytical
and preanalytical factors, but also in staining interpret-
ation and scoring [11]. Importantly, attempts to reduce
the high discordance rates either by means of formal
counting quantification methods (as opposed to simple
eyeballing) or by training of individuals have not been
successful [12].
Despite methodological concerns, overall a strong
correlation of Ki-67 with breast cancer outcome is suf-
ficiently supported, particularly by data originating from
randomized clinical trials with central review of bio-
markers [10]. This has also been shown in the neoadju-
vant setting, where higher Ki-67 values are consistently
associated with higher rates of pathological complete re-
sponse (pCR) [13], a finding which reflects the fundamen-
tal link between tumor replication fraction and activity of
cytotoxic agents. Still it remains difficult to identify a rea-
sonable cut-off to predict pCR [14].
Two techniques which could circumvent the inter- or
intra-observer variability of Ki-67 manual microscopic
assessment are automated image analysis and reverse
transcription quantitative real-time PCR (RT-qPCR). A
trained human eye may achieve an excellent under-
standing of images and patterns, but is less accurate
when it comes to quantification. Computer-based vi-
sion methods could represent a solution to this prob-
lem by offering standardized image processing and
reliable quantification [15]. However with regard to the
assessment of tumor proliferation, the areas of interest
and staining intensities have to be defined, and mea-
sured reproducibly. Also, it is still under debate how to
deal with areas of increased proliferative activity (hot
spots), and if low intensity staining should be taken into
account [16]. Therefore, automated estimations of Ki-
67 are highly correlated with manual assessments, but
it is not yet certain whether or not they can improve
prediction and prognostication [17–19].
RT-qPCR has a series of widely acknowledged meth-
odological advantages over IHC, which appear particu-
larly beneficial in the context of reducing the bias of
routine Ki67 assessment; it is quantitative by nature with
much wider dynamic range, it does not require an expe-
rienced eye, and results are not affected by subjective
interpretations [20]. Moreover, access to standardized
protocols and automation ensures accurate performance
and fast turn-around. In recent years highly specific and
sensitive techniques have been developed, which allow
for fast and efficient extraction of high-quality nucleic
acids from FFPE overcoming the challenges posed by
fixation and embedding [21].
Validation of the various available methods for the
assessment of Ki-67 requires comparative testing prefera-
bly in a specifically defined clinical context. In the present
study we used the neoadjuvant setting of a phase II trial
randomizing patients receiving anthracyclin/taxane based
standard treatment between pemetrexed and cyclophospa-
mide in order to directly compare the assessment of Ki-67
with automatic, quantitative read-out of IHC (qIHC) and
the determination of tumor MKI67 mRNA with RT-qPCR
on FFPE tissue extracted RNA.
Methods
Study population
Core needle biopsies from 101 out of 105 patients (96,2%)
with primary invasive breast cancer, that had been
enrolled in the H3E-MC-S080 (NCT00149214, Sponsor:
Eli Lilly and Company) neoadjuvant phase II study [1],
were obtained. All patients had been diagnosed with oper-
able (T2-T4/N0-2/M0) breast cancer at a single institution
(National Center for Tumor Diseases, University-Hospital,
Heidelberg) had been randomized to receive sequential
anthracycline/taxane-based regimens containing either
pemetrexed or cyclophosphamide in combination with
epirubicin. A written informed consent for the research
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use of patient biological material was granted at the time
of enrolment. The study was approved by the local ethics
committee. Complete molecular data (including RT-qPCR
data) and clinical follow-up information were available in
83 out of 105 (79%) patients (statistics data set #1). Ki-67,
ER, and PR IHC slides were available in 54 (51%) patients
for quantitative IHC (statistics data set #2).
Isolation of tumor RNA
For RNA extraction from FFPE tissue, a single 10 μm curl
was processed according to a commercially available
bead-based extraction method (RNXtract® kit; BioNTech
Diagnostics GmbH, Mainz, Germany). In brief, a lysis
buffer was used to liquefy FFPE tissue slices while melting
of paraffin was carried out in a thermo-mixer. Tissue
lysis was accomplished with a proteinase K solution.
Thereafter, lysates were admixed with germanium-
coated magnetic particles in the presence of special
buffers, which promote the binding of nucleic acids.
Purification was carried out by means of consecutive
cycles of mixing, magnetization, centrifugation and
removal of contaminants. RNA was eluated with 100 μl
elution buffer and RNA eluates were then stored at
−80 °C until use.
Gene expression by RT-qPCR
The MammaTyper® is a molecular in vitro diagnostic
tool for the assessment of the gene expression levels of
the four cancer biomarkers that are required for the
clinical management of breast cancer patients in daily
routine clinical practice. Instead of using IHC to assess
protein expression of HER2, ERα, PR, and Ki-67, with
MammaTyper®, it is possible to measure the mRNA
transcripts of the corresponding genes (ERBB2, ESR1,
PGR, and MKI67), doing so by using routine FFPE
material and by achieving accurate, reproducible and
objective results. The gene expression data may be then
integrated so as to assign individual samples to a mo-
lecular subtype of breast cancer.
The mRNA expression levels of ERBB2, ESR1, PGR,
and MKI67 as well as of two reference genes (REF),
namely B2M and CALM2, were determined by RT-
qPCR, which involves reverse transcription of RNA and
subsequent amplification of cDNA executed successively
as a 1-step reaction. In MammaTyper®, the 6 assays
(assay = primer pair and probe specific for the respective
target sequence) are duplexed into three assay mixes,
each using a pair of hydrolysis probes labelled with differ-
ent fluorophores for separate detection of the duplexed
assays [22].
Each patient sample or control was analyzed with each
assay mix in triplicates. The experiments were run on a
Versant kPCR Molecular System (Siemens Healthcare,
Erlangen, Germany) according to the following protocol:
5 min at 50 ° C, 20 sec at 95 ° C followed by 40 cycles of
15 sec at 95 ° C and 60 s at 60 ° C and according to
MammaTyper® instructions for use 140603-90020-EU
Rev 2.0.
Forty amplification cycles were applied and the cycle
quantification threshold (Cq) values of MKI67 and the
two REF genes for each sample (S) were estimated as the
median of the triplicate measurements. These were then
normalized against the mean expression of the REF
genes and set off against a calibrator (PC), to correct for
inter-run variations (ΔΔCq method) (Livak et al. 2001).
The final values were generated by subtracting ΔΔCq
from the total number of cycles to ensure that normal-
ized gene expression obtained by the test is proportional
to the corresponding mRNA expression levels, a method
that facilitates interpretation of data and clinicopathologi-
cal correlations. The various calculation steps are summa-
rized in the following formula:
40‐ΔΔCq MKI67ð ÞS ¼ 40‐ð Cq MKI67½ S – meanCq REF½ Sð Þ
– Cq MKI67½ pc – meanCq REF½ pcð ÞÞ
In 18 patients the MammaTyper® assay failed, because
the required amount of RNA was not sufficient for
analysis according to pre-specified criteria as described
in the instructions for use.
Pathology and Immunohistochemistry
Tumor grading, tumor typing and immunohistochem-
istry (ER, PR, Ki-67) was performed on the pretreat-
ment core biopsies on all patients. Pathological
complete response (pCR) was determined on tumor
resection specimens after completion of neoadjuvant
chemotherapy, and was defined as no evidence of re-
sidual invasive and ductal disease in the breast and
lymph nodes (ypT0,ypN0).
Immunohistochemistry was performed according to
previously standardized protocols on an automated IHC
platform (Dako Techmate 500) with citrate buffer for
antigen retrieval [23] and observing the ASCO/CAP
guidelines for immunohistochemistry [7]. The following
primary antibodies and corresponding dilutions were
used (DakoCytomation, Glostrup, Denmark): ER (clone
1D5, 1:100), PR (clone PgR636, 1:100) and Ki-67 (MIB-1,
1:200). Slides were assessed by quantitative image ana-
lysis (qIHC) using the Aperio Image Analysis toolbox
(Leica Biosystems, Nussloch, Germany). Staining inten-
sity and percentage of positive nuclei were recorded after
manually segmenting tumor from adjacent stroma.
Tumors with ER/PR Remmele scores greater than 3 or
positive nuclei greater than 1% were considered hor-
mone receptor positive.
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Statistical methods
The Spearman correlation coefficient r was used as a
measure of the strength and direction of the linear rela-
tionship between variables. 2×2 contingency tables were
used to calculate positive percent agreement (PPA) and
negative percent agreement (NPA) as a measure of agree-
ment: PPA = 100% x a/(a + c), NPA = 100% x d/(b + d).
Receiver Operating Characteristics (ROC) analysis was
performed to determine the optimal cut-off for Mamma-
Typer® gene and qIHC protein measurements with pCR
as the endpoint. ROC analysis instead of comparing odds
ratios to take into account the ratios of clinically relevant
false positive and false negative determinations and to
identify cut points for each method at clinically relevant
prerequisites (i.e., detect all responding tumours). ROC
analysis has been used to objectively address each method
providing different result codings in a non-parametric
manner [24]. On the other hand ROC analysis bears the
risk of misinterpreting clinical validity when analyzing
heterogeneous populations [25]. However, we have ana-
lyzed the response to neoadjuvant chemotherapy within
controlled, randomized phase II trial which has defined
inclusion and exclusion criteria to have the most compar-
able basic risk situation. As optimal cut-off for the identifi-
cation of complete response by the methodologies the
point of highest sensitivity still retaining 100% specificity
was chosen. The p value reported for evaluating the ROC
curve tests the null hypothesis that the area under the
curve really equals 0.50 as provided by the statistical pro-
gram used (GraphPad Prism). The non-parametric Mann-
Whitney test was used to confirm the statistical signifi-
cance when comparing responding versus non-responding
tumors and box plots were used to illustrate each case of
responding and non-responding tumor above and below
the cut-off value. Statistical analyses were performed with
JMP SAS (SAS Institute, Cary, NC, USA) and Graph Pad
Prism software (Version 5.04; Graph Pad Software Inc., La
Jolla, CA, USA).
Results
Patient population
Biopsy tissue was available from 101 out of 105 patients.
Gene expression analysis by MammaTyper® was successful
in 83 biopsy specimens with full clinical data out of a total
of 105 trial participants (Fig. 1). 12 patients out of this
group had achieved complete pathological remission
(pCR). Basic clinicopathological characteristics of statistics
data set #2 that includes quantitative IHC data is listed in
Table 1.
Comparison of IHC with RT-qPCR based assessment of ER,
PR and Ki-67
Comparing qIHC of ER with RT-qPCR of ESR1
demonstrated a good overall agreement of 96,6% (PPA
100%; NPA 92.3%) as well as a good correlation looking at
the continuous data (spearman’s r = 0.82, p < 0.0001).
Correlation between vIHC of ER and RT-qPCR for ESR1
(spearman’s r = 0.85, p < 0.0001) and between vIHC and
qIHC ER (spearman’s r = 0.88, p < 0.0001) was high, too.
Fig. 1 Remark diagram of sample selection
Table 1 Basic tumor characteristics
no-pCR pCR
Histological Type p= 0.39
Invasive ductal NOS 37 82.2% 9 100.0%
Invasive lobular 7 15.6% 0 0.0%
Other 1 2.2% 0 0.0%
Histological Grade p= 1.00
Grade 2 15 33.3% 3 33.3%
Grade 3 30 66.7% 6 66.7%
ypT Category p= 0.81
ypT0 0 0.0% 9 100.0%
ypT1 27 50.0% 0 0.0%
ypT2 9 20.0% 0 0.0%
ypT3 8 17.8% 0 0.0%
ypT4 1 2.0% 0 0.0%
ypN Category p= 0.81
ypN0 27 50.0% 9 100.0%
ypN+ 25 46.3% 0 0.0%
ypNX 2 3.7%
HER2 status p= 0.68
Neg 36 66.7% 7 13.0%
Pos 7 13.0% 2 3.7%
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Overall agreement for PR protein and PGR mRNA ex-
pression was 91.4% (PPA 83.3%; NPA 100%) comparing
qIHC and RT-qPCR and there was a high correlation for
the continuous data (r = 0.86, p < 0.0001). Correlation
between vIHC and RT-qPCR and between vIHC and
qIHC was very high, too (r = 0.88, p < 0.0001 and r = 0.90,
p < 0.0001, respectively). Concordance when comparing
visual IHC protein with RT-qPCR RNA expression was
good for ESR1 as well as for PGR, although slightly lower
compared to the agreement between qIHC and RT-qPCR
(OPA 91.2%; PPA 90.9%; NPA 91.7%) and for PGR (OPA
92.9%; PPA 88.0%; NPA 96.9%, respectively). For both,
ESR1 and PGR, only 4 cases were discordant, with 3 cases
each positive by vIHC and negative by RT-qPCR, while 1
case was negative by vIHC and positive by RT-qPCR
(Fig. 2). However, several of these discrepancies could be
resolved by using quantitative IHC, as these cases were
also discrepant when comparing vIHC with qIHC. More-
over, qIHC could delineate quantitative differences of
hormone receptor expression at the highest Remmele
Score value of 12, where vIHC could not resolve expres-
sion differences. In addition, at the lower range of ex-
pression levels RT-qPCR based assessment could still
determine substantial differences of mRNA levels while
the IHC based assessment could not detect any protein
expression. The inter-gene spearman correlation was
moderate for ESR1 and PGR (r = 0.59, p < 0.0001), while
Ki-67 correlated negatively with PGR (−0.37, p = 0.007).
While the correlation for ESR1 and PGR protein and
RNA expression was high when comparing IHC with RT-
qPCR results (spearman’s r = 0.82, p < 0.0001 and r = 0.86,
p < 0.0001, respectively), the correlation between MKI67
protein and RNA expression was only moderate (spear-
man’s r = 0.56 for vIHC and r = 0.47 for qIHC). In contrast
the correlation between both methods for Ki-67 assess-
ment by IHC was high (r = 0.80, p < 0.0001). The median
value of Ki-67 proliferation index by image analysis IHC
(qIHC) was 23.4%, by conventional visual IHC (vIHC)
Fig. 2 Correlation of RT-qPCR for ESR1, PGR and MKI67 with quantitative IHC by image analysis (a, c, e) and visual IHC assessment (b, d, f)
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35.0%, and 37.01 for RT-qPCR, clearly reflecting the inclu-
sion criteria of the S080 trial which targeted clinically
higher-risk patients. Scatter plot analysis displays the posi-
tive correlation between RT-qPCR and visual as well as
quantitative IHC assessment in Fig. 4.
Prediction of pCR
To compare the clinical utility we performed a ROC
analysis to determine the optimal cutoff for predicting
the pCR. The results of the ROC analysis are presented
in the graphical plots of Fig. 3. With RT-qPCR, 100% of
responders could be detected with a specificity of 68.9%
at a 40-ddCT level of 37.31 which almost reflected the
median mRNA expression in this cohort (Fig. 3a, b).
Conversely, no responder was below RT-qPCR of 37.31
(Fig. 4a). For IHC assessment, it was difficult to deter-
mine a reliable cutoff reaching high sensitivity and speci-
ficity. With RT-qPCR the area under the curve was 0.78
for the overall cohort and 0.80 for the IHC cohort
(Statistics #2) (p = 0.002 and p = 0.004). For both IHC
methods, the ROC was not significant.
Since maximum sensitivity was a pre-requisite, the
two methods were compared with respect to specifi-
city, which was found to be substantially higher for
MammaTyper® (68.9%) compared to qIHC (22.2%).
Using the cut-offs indicated by ROC analysis (37.31
for RT-qPCR, 13.2% for qIHC and 3.5% for vIHC),
tumors were characterized as bearing either high or
low MKI67 RNA or Ki-67 protein expression, respect-
ively. However, as illustrated in Fig. 4, statistically
significant differences between groups were found for
the RT-qPCR but not for IHC methods when patients
were stratified according to proliferation and pCR
(Mann–Whitney p = 0.003 and p = 0,005 for RT-qPCR
and p = 0.099 for qIHC and p = 0.133 for vIHC).
Using the cut-offs obtained by ROC analysis, pCR
was observed in 9 of 24 patients (37.5%, p < 0.001)
with high MKI67 RNA expression but in no patient
with low RNA expression. Accordingly for qIHC, pCR
was observed in 9 of 44 patients (20.5%, p = 0.27)
with high Ki-67 labelling index and similarly it was
entirely lacking in patients with low proliferation. For
RT-qPCR the ROC analysis was also highly significant
Fig. 3 ROC analysis for prediction of pathological complete response by quantifying MKI67/Ki-67 expression by RT-qPCR (a, b) and IHC (c, d) showing
overall increased ability of mRNA assessment to correctly identify responders versus non-responders
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when only luminal tumors had been assessed, though the
sample size was small in this subset (data not shown).
Discussion
In this study we have validated clinical performance of
hormone receptor gene expression by RT-qPCR by com-
paring predefined cut-offs in a blinded fashion with the
current standard of IHC. Furthermore, we have investi-
gated the diagnostic performance of two methods for
assessing MKI67 gene expression, namely IHC with com-
puterized quantification of protein and RT-qPCR RNA
quantification with the MammaTyper® IVD kit in the
setting of pCR prediction. When continuous data were di-
chotomized to reflect high- and low-MKI67 categories
with cut-offs obtained by ROC curve analysis after consid-
ering 100% sensitivity, RT-qPCR was significantly more
specific than qIHC.
To the best of our knowledge this is the first direct
comparison of this kind in the context of a clinical trial.
For the mRNA estimation we used the MammaTyper®, a
novel in vitro diagnostic test for breast cancer molecular
subtyping. To prove the clinical utility of mRNA based
assessment, we compared RT-qPCR with conventional
visual assessment as well as digital image analysis based
determination at a reference pathology lab in the context
of a clinical trial. Moreover, the methods were examined
with respect to their ability to predict pCR according to
Ki-67 protein or MKI67 mRNA expression levels mea-
sured on pretreatment core biopsies. Our results indi-
cate, that, when using RT-qPCR valid cut-offs for
mRNA expression, which reliably distinguish between
non-responding and responding tumors as determined
by pCR (ypT0 ypN0) can be identified.
Pathological complete response has gained wide ac-
ceptance as one of the strongest predictors of prolonged
survival in the setting of neoadjuvant chemotherapy
[26, 27]. Therefore, laboratory assays that can efficiently
predict a patient’s response to a given preoperative
chemotherapeutic combination may serve as tools for
individualizing treatment and improving long-term out-
comes [28]. As with adjuvant chemotherapy, neoadju-
vant regimens also suffer from the fact that substantial
therapeutic benefit is restricted only to a fraction of
those treated, whereas all patients will experience ad-
verse events because of toxicity [29].
In several neoadjuvant studies Ki-67 protein expres-
sion has been investigated in pre-operative biopsies in
relation to the response to treatment and in most cases
a high Ki-67 proliferation rate was predictive of higher
probability of pCR [13]. Fasching et al. analyzed Ki-67
by conventional IHC in core biopsies from 552 patients
from a single German institution and showed that a
pre-defined 13% cut-off could predict pCR with 94%
sensitivity and 36% specificity [30]. Interestingly, our
ROC analysis for qIHC requiring 100% sensitivity with
the least possible loss on specificity led to an identical
cut-off (13.2%) for Ki-67. However, this finding requires
careful interpretation, due to differences characterizing
the clinical settings between the two neoadjuvant stud-
ies and the original work by Cheang [31]. In the latter
case, the Ki-67 cut-off was fine-tuned against gene ex-
pression profiling in order to distinguish Luminal A
from Luminal B tumors in a population containing
both high- and low-risk breast cancers, whereas in the
neoadjuvant setting the same cut-off was intended to
identify the majority of, mainly high-risk, patients that
would most likely benefit from preoperative cytotoxic
therapy.
Alike what has been repeatedly shown in the adjuvant
setting, it appears that the molecular architecture of tu-
mors as defined by the expression of hormone receptors
and HER2/neu may act as a modifier of the association
between Ki-67 and response to neoadjuvant treatment
Fig. 4 Scatter plots illustrating the distribution of RT-qPCR mRNA
(upper panel) and qIHC (lower panel) and vIHC (right panel) protein
measurements in relation to the groups of responders (green dots)
and non-responders (blue dots). Differences were tested with the
Mann-Whitney test (a = data set 1, n = 83, b, c, d = common data
set, n = 54)
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and between pCR and long-term outcomes [14, 32].
While 101 tumors were available for analysis, the inclu-
sion of 83 or 54 tumors in this study was not based on a
statistical rational but was dictated by the availability of
tumor tissue with complete RT-qPCR and qIHC data.
A novel aspect of the present work is the comparison
between protein-based and mRNA-based methods for the
assessment of tumor proliferation. Our findings highlight
the feasibility of using RT-qPCR for the routine assess-
ment of ESR1, PGR & MKI67 in order to assist the selec-
tion of breast cancer patients for neoadjuvant treatment.
Even though both RT-qPCR and qIHC of MKI67/Ki-67
could be calibrated to maximize negative predictive value,
only with the former this was achieved whilst ensuring
sufficient specificity, which if validated would signify
that MammaTyper® could help a considerable number
of patients safely forego unnecessary treatment. These
data collectively indicate that MammaTyper®MKI67
RNA was overall more representative of the true prolif-
eration state of the tumor than was computer assisted
Ki-67 protein estimation, a finding that is worth valid-
ating in larger datasets.
Significant correlations between conventional Ki-67
visual assessment and RT-qPCR have been previously
reported [33, 34], indicating a strong biological link be-
tween mRNA and protein expression despite methodo-
logical variations, as is further indicated by comparable
prognostic hazard ratios obtained by both methods
[35]. To the best of our knowledge however, our study
is the first to compare image analysis with RT-qPCR for
the assessment of tumor proliferation with the add-
itional advantage of using material from a randomized
clinical trial. The correlation between mRNA and pro-
tein was significant but moderate, a finding which may
reflect post translational modifications or may be re-
lated to the increased dynamic range of RT-qPCR as
compared to IHC. Another possible explanation might
be that mRNA levels are a reflection of the average
gene expression in the entire FFPE slice, whereas IHC
may be biased in favor of selected “representative”
tumor areas. Even in the case of image analysis systems,
inspection of digitalized images and manual identifica-
tion of tumor areas is necessary before automatic
scoring.
Computerized methods have been recommended as a
solution to the problem of subjectivity in the visual
assessment and scoring of IHC-stained slides. Not sur-
prisingly, Ki-67 scores from image analysis systems are
generally in close agreement with those of manual
methods because manual scoring for research purposes
is customarily performed by a pathologist with long-
standing experience in the field [17, 36]. It is worth
mentioning, however, that in a routine decentralized
setting, digital processing and scoring of slides would
probably outperform manual assessment which is prone
to considerable subjectivity often not improved upon
standardization [37]. Digital analysis yields more repro-
ducible results with regard to staining intensity, by
facilitation the definition of low grade staining inten-
sities. Definitive conclusions would require compari-
sons between all three methods (central versus local
versus automatic) performed preferably in the prospect-
ive retrospective setting of a large multi-center trial.
Multi-gene molecular signatures have also been
tested as a way for predicting pCR in patients with
breast cancer [38–40]. However, generalized use of
these commercialized assays is limited by their in-
creased cost and the requirement to run in centralized
platforms or both. Interestingly, proliferation genes, in-
cluding MKI67, are often heavily weighted in multi-
gene scores which serve as estimators of a patients’ risk
of developing recurrences. This is perhaps one of the
reasons why multi-gene tests do not always prove to be
convincingly superior to conventional or less sophisticated
methods for tumor risk stratification [35, 41, 42], leading
some authors to question their cost-effectiveness [43].
Moreover, for several commercially available tests, neither
doctors nor consumers can gain access to the continuous
expression data of individual proliferation markers that
make up the final risk scores. This restriction overall
minimizes the possibility of potentially interesting com-
parisons between proliferation motifs or scores and sin-
gle proliferation markers based on RT-qPCR or IHC.
Strikingly, our ROC curve analysis of MKI67 40-ΔΔCq
values for the prediction of pCR displayed performance
characteristics that are comparable with those of a 50-
gene predictor of tumor recurrence risk developed by
supervised training of Cox models [39]. Along these
lines, single-gene MKI67 RT-qPCR may be worth con-
sidering as a golden means for assessing tumor prolifer-
ation due to its unique ability to combine technical
advancements and diagnostic accuracy with more af-
fordable pricing.
Conclusions
Image analysis-assisted scoring of ER, PR and Ki-67
IHC and quantification of ESR1, PGR and MIKI67
RNA expression with RT-qPCR both represent promis-
ing alternatives to conventional visual estimation and
may assist in improving reproducibility and accuracy in
the field. However, RT-qPCR assessment of tumor pro-
liferation was overall more accurate than quantitative
IHC. This is the first study to compare tumor MKI67
gene expression by RNA and protein assessment in a
prospective retrospective neoadjuvant setting. Due to
the relatively small sample size, these data should be
considered preliminary and worth validating in larger
datasets.
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